TCT-53
Drug Eluting Stents In Female Diabetic Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
SUYOUNG JANG1, MYUNGHO JEONG2, Ji Eun Song1, Gyeong Sik Chang2
1Chonnam National University Graduate School of Medical Science, Gwangju, Korea, Republic of, 2Chonnam National University, Gwangju, Korea, Republic of.

Background: The aim of study was to compare different coronary stents used during primary percutaneous coronary intervention (PCI) in female patient with acute myocardial infarction (AMI) and diabetes mellitus (DM).

Methods: We selected 1799 consecutive AMI female patients (68.9±10.2) with DM undergoing primary PCI and divided them into 5 groups based on the types of drug eluting stents implanted. Sirolimus-eluting stent (SES), Paclitaxel-eluting stent (PES), Everolimus-eluting stent (EES), Biolimus-eluting stent (BES), Zotarolimus-eluting stent (ZES). Study end point was 12-month major adverse cardiac events (MACE), a composite of death, fatal and nonfatal myocardial infarction and target vessel revascularization.

Results: Mean Hemoglobin A1c level of SES, PES, BES, ZES was 8.3%, 8.9%, 4.2%, 4.5%, and 5.2%, respectively (p<0.001). Kaplan Meier analysis show significant difference between SES and BES (p=0.046), SES and PES (p=0.025), PES and BES (p=0.039), PES and EES (p=0.011). Independent predictors of one-year MACE were family history (OR 1.649, 95% CI 0.929-2.930, p=0.076), serum glucose level(OR 0.304, 95% CI 0.140-0.661, p=0.024), serum creatine level (OR 3.933, 95% CI 1.194-12.96, p=0.02). In female patient with AMI and DM, EES and SES would be better therapeutic option than SES and PES for one-year follow up and this result warranted further long-term follow-up.

TCT-54
Additive Prognostic Value Of The Global Registry Of Acute Coronary Events Score Over Other Risk Scores For In-Hospital Outcome Prediction In Patients Presenting With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Lorenzo Azizali1, Razl Khan2, Malek Al-Hawwas1, Rajaa Hatem1, Annik Fortier1, Philippe L. L Allier1, Hung Q. Ly1
1Montreal Heart Institute, Montreal, QC, Canada

Background: Risk stratification is of utmost importance in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). We aimed to compare different risk scores to evaluate their predictive power towards in-hospital outcomes.

Methods: In 241 consecutive STEMI patients referred for pPCI, the GRACE, TIMI, Zwolle, CADILLAC, PAMI, SYNTAX, and residual SYNTAX (rSS) scores were calculated. The endpoints of this study were in-hospital death, major adverse cardiac events (MACE: death, recurrent myocardial infarction and urgent revascularization) and major adverse events (MAE: MACE, heart failure, stroke, acute kidney injury and major bleeding). The C-statistic was used for comparisons.

Results: Mean age was 62.2±12.6 years, 77.2% were male and 16.2% diabetics. Mean ejection fraction was 47.8±9.6%. The culprit lesion was the LAD in 38.6% and 44.4% rather than the circumflex artery. All scores were significantly associated with the 3 outcomes on univariate analysis, except the rSS (with death, MACE and MAE). As shown in the Table, the GRACE score showed the highest C-statistic for all endpoints: death (0.8866, 95% CI: 0.8508 to 0.9174), MACE (0.8168; 95% CI: 0.7078 to 0.9258) and MAE (0.7022; 95% CI: 0.7151 to 0.8693). The GRACE score significantly outperformed the other 6 scores for all 3 endpoints (except the Zwolle and CADILLAC risk scores for MAE).

Conclusions: In a contemporary population of STEMI patients treated with pPCI, the GRACE score was the best predictor of in-hospital death, MACE and MAE.

TCT-55
Has PRAMI Changed Practice? An International Survey of Approaches to the Management of Non-Culprit Lesions in Patients Undergoing Primary Percutaneous Coronary Intervention (PCI) for ST-Elevation Myocardial Infarction (STEMI)
Novalia Parnama Siddik1, Colin Berry2, ERIC ECKHOUT1, Edilth McGinnigle1, James T. Stewart1, Keith G. Oldroyd1
1Golden Jubilee National Hospital, Glasgow, United Kingdom, 2University of Glasgow / Golden Jubilee National Hospital, Glasgow, United Kingdom.

Background: The recent PRAMI trial has shown that in patients with STEMI immediate preventive PCI to non-culprit lesions reduced the risk of major adverse cardiovascular events (MACE). We conducted an online survey to assess current approaches and to determine whether the PRAMI results are being translated into clinical practice.

Methods: Email invitations to participate in a SurveyMonkey® questionnaire were sent to interventional cardiologists in the United Kingdom (UK), United States of America (USA), Switzerland and Australia and New Zealand (ANZ).

Results: Of the 288 responses, 146 (50.7%) were from the UK, 59 (20.5%) from the USA, 39 (13.6%) from Switzerland and 44 (15.2%) from ANZ. The majority of respondents opted for medical therapy for lesions of 50-70% severity (n=196, 76.1%) and staged PCI for lesions of 70-90% severity (n=203, 76.6%). In patients with >90% stenosis, 28.2% (n=179) for staged PCI. Respondents most frequently opted to perform staged PCI during the index admission for stenoses of >90% severity (n=121, 47.8%) and to delay it for 4-6 weeks for other lesion severities (n=192, 43.7%). Most respondents were either uncertain that immediate preventive PCI prevents MACE (n=119, 41.3%) or did not believe that it does (n=125, 43.4%).

Conclusions: Only a minority of interventional cardiologists are persuaded that preventive PCI reduces the risk of MACE. Furthermore, most would perform staged rather than immediate PCI. Further studies are required to confirm or refute the PRAMI results and to address the optimal timing of PCI to non-culprit lesions.

TCT-56
Correlation Between Residual Platelet Reactivity After Clopidogrel Loading And Long Term Major Adverse Outcome Among STEMI Patients Undergoing Delayed Primary Percutaneous Coronary Intervention
Manolis Varvarinas1, Konstantinos Kalogerou1, NIKOLAOS DAGRES1, Maria Kariori3, Maria Lavda4, Carmen Moldovan3, Evangelia Bei5, Dimitrios A. Vrachas1, Christodoulos Stefanidis1
111st Dept. of Cardiology, Hippokration Hospital, Medical School of Athens, Athens, Greece, 2nd Department of Cardiology, University of Athens, Atikon Hospital, athens, Greece, 11th Department of Cardiology, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece, 1st Department of Cardiology, Hippokration Hospital, athens, Greece, 1st Department of Cardiology, ATHENS, Greece, 1st Department of Cardiology, Hippokration Hospital, Athens, Greece, 7Athens Medical Center, Athens, Greece

Background: It has been shown that higher Residual Platelet Reactivity RPR (P2Y12-Reaction-Units,PRU>251.5) after clopidogrel loading is associated with larger intracoronary thrombus burden, as well as with impaired myocardial perfusion